All In Biotech

Drug Trial Radar · NCT05822544

Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes

A Phase 1/1b Study of Single and Multiple Ascending Doses of TLC 6740 in Healthy Subjects, Including Evaluation of Food Effect and Potential Drug-Drug Interactions, and Preliminary Safety and Efficacy in Subjects With Obesity, With or Without Diabetes

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 564 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

564

Planned (sponsor's estimate)

Start

Apr 22, 2023

Primary completion

Sep 2026

Study completion Jan 2027

Sponsor

Lead sponsor
OrsoBio, IncIndustry
Sponsor type
Industry
First posted
Apr 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects. The phase 1b portion of the study is designed to assess the safety, tolerability, and PK of TLC-6740 in subjects with obesity, with or without type 2 diabetes mellitus.

Conditions

  • Healthy Subjects
  • Obesity
  • Type 2 Diabetes

Interventions

  • TLC-6740 Oral SolutionDrug

    Oral solution of TLC-6740

  • Placebo Oral SolutionOther

    Placebo-to-match oral solution TLC-6740

  • TLC-6740 TabletDrug

    Tablet formulation of TLC-6740

  • Drug Metabolizing EnzymeDrug

    Oral dose of omeprazole, voriconazole, itraconazole, or rifampicin

  • TirzepatideDrug

    Subcutaneous injection of tirzepatide

  • Placebo TabletOther

    Placebo-to-match tablet formulation of TLC-6740

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of TLC-6740 treatment-emergent adverse eventsTime frame: Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study
  2. PK of TLC-6740 AUCTime frame: Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study
  3. PK of TLC-6740 CmaxTime frame: Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study
  4. PK of TLC-6740 tmaxTime frame: Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study
  5. PK of TLC-6740 t1/2Time frame: Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study
  6. PK of TLC-6740 CL/FTime frame: Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • OrsoBio Auckland Research Site 1

    Auckland, New Zealand

  • OrsoBio Auckland Research Site 2

    Auckland, New Zealand

  • OrsoBio Auckland Research Site 3

    Auckland, New Zealand

  • OrsoBio Research Site

    Christchurch, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.